scholarly journals Impact of postdiagnostic statin use on ovarian cancer mortality: A systematic review and meta-analysis of observational studies

2018 ◽  
Vol 84 (6) ◽  
pp. 1109-1120 ◽  
Author(s):  
Xia Li ◽  
Jing Zhou
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Cancer Mortality ◽  
Observational Studies ◽  
Meta Analysis ◽  
Statin Use

Dietary Fat Intake and Risk of Ovarian Cancer: A Systematic Review and Dose–Response Meta-Analysis of Observational Studies

2019 ◽  
Vol 71 (6) ◽  
pp. 939-953 ◽  
Author(s):  
Alireza Sadeghi ◽  
Sakineh Shab-Bidar ◽  
Mohammad Parohan ◽  
Kurosh Djafarian
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Dose Response ◽  
Dietary Fat ◽  
Observational Studies ◽  
Meta Analysis ◽  
Fat Intake ◽  
Dietary Fat Intake

scholarly journals Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer

2020 ◽  
Vol 31 (10) ◽  
pp. 869-879
Author(s):  
Sarah Irvin ◽  
Megan A. Clarke ◽  
Britton Trabert ◽  
Nicolas Wentzensen
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Meta Analysis ◽  
The Relationship ◽  
Statin Use

The Effects of Metformin on Ovarian Cancer: A Systematic Review

2013 ◽  
Vol 23 (9) ◽  
pp. 1544-1551 ◽  
Author(s):  
Piyemeth Dilokthornsakul ◽  
Nathorn Chaiyakunapruk ◽  
Wichai Termrungruanglert ◽  
Chayanin Pratoomsoot ◽  
Surasak Saokeaw ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Cancer Prevention ◽  
Observational Studies ◽  
Cancer Survival ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Survival Outcomes ◽  
Diabetic Patients ◽  
Therapeutic Effects

ObjectiveThe potential therapeutic effects of metformin on several cancers were reported. However, the evidence of the effects of metformin on ovarian cancer is still limited and inconclusive. This systematic review and meta-analysis study aims to summarize the existing evidence of the therapeutic effects of metformin on ovarian cancer.MethodsWe performed systematic searches using electronic databases including PubMed and EMBASE until December 2012. Key words included “metformin” AND (“ovarian cancer” OR “ovary tumor”). All human studies assessing the effects of metformin on ovarian cancer were eligible for inclusion. All articles were reviewed independently by 2 authors with a standardized approach for the purpose of study, study design, patient characteristics, exposure, and outcomes. The data were pooled using a random-effects model.ResultsOf 190 studies retrieved, only 3 observational studies and 1 report of 2 randomized controlled trials were included. Among those studies, 2 reported the effects of metformin on survival outcomes of ovarian cancer, whereas the other 2 reported the effects of metformin on ovarian cancer prevention. The findings of studies reporting the effects on survival outcomes indicated that metformin may prolong overall, disease-specific, and progression-free survival in ovarian cancer patients. The results of studies reporting the effects of metformin on ovarian cancer prevention were meta-analyzed. It indicated that metformin tended to decrease occurrence of ovarian cancer among diabetic patients with the pooled odds ratio of 0.57 (95% confidence interval, 0.16–1.99).ConclusionsOur findings showed the potential therapeutic effects of metformin on survival outcomes of ovarian cancer and ovarian cancer prevention. However, most of the evidence was observational studies. There is a call for further well-conducted controlled clinical trials to confirm the effects of metformin on ovarian cancer survival and ovarian cancer prevention.

scholarly journals Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
K Awad ◽  
M Mohammed ◽  
M M Zaki ◽  
A I Abushouk ◽  
G Y H Lip ◽  
...  
Keyword(s):  
Systematic Review ◽  
Primary Prevention ◽  
Older People ◽  
Lower Risk ◽  
Observational Studies ◽  
Meta Analysis ◽  
Case Control ◽  
Current Evidence ◽  
All Cause Mortality ◽  
Statin Use

Abstract Background Current evidence from randomized controlled trials on statins for primary prevention of cardiovascular disease (CVD) in older people, especially those aged >75 years, is still lacking. Purpose We conducted a systematic review and meta-analysis of observational studies to extend the current evidence about association of statin use in older people primary prevention group with risk of CVD and mortality. Methods PubMed, Scopus, and Embase were searched from inception until March 18, 2021. We included observational studies (cohort or nested case-control) that compared statin use vs non-use for primary prevention of CVD in older people aged ≥65 years; provided that each of them reported the risk estimate on at least one of the following primary outcomes: all cause-mortality, CVD death, myocardial infarction (MI), and stroke. Risk estimates of each relevant outcome were pooled as a hazard ratio (HR) with a 95% confidence interval (CI) using the random-effects meta-analysis model. Results Ten observational studies (9 cohort and one case-control study; n=872,845) fulfilled our criteria. The overall combined estimate suggested that statin therapy was associated with a significantly lower risk of all-cause mortality (HR: 0.86 [95% CI: 0.79 to 0.93]), CVD death (HR: 0.80 [95% CI: 0.78 to 0.81]), and stroke (HR: 0.85 [95% CI: 0.76 to 0.94]) and a non-significant association with risk of MI (HR: 0.74 [95% CI: 0.53 to 1.02]). The beneficial association of statins with the risk of all-cause mortality remained significant even at higher ages (>75 years old; HR: 0.88 [95% CI: 0.81 to 0.96]) and in both men (HR: 0.75 [95% CI: 0.74 to 0.76]) and women (HR: 0.85 [95% CI: 0.72 to 0.99]). However, this association with the risk of all-cause mortality remained significant only in those with DM (HR: 0.82 [95% CI: 0.68 to 0.98]) but not in those without DM. Conclusions Statin therapy in older people (aged ≥65 years) without CVD was associated with a 14%, 20% and 15% lower risk of all-cause mortality, CVD death and stroke, respectively. The beneficial association with the risk of all-cause mortality remained significant even at higher ages (>75 years old), in both men and women, and in individuals with DM, but not in those without DM. These observational findings support the need for trials to test benefits of statins in those above 75 years of age. FUNDunding Acknowledgement Type of funding sources: None. Figure 1. Results of the meta-analysis

scholarly journals Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies

BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Kamal Awad ◽  
Maged Mohammed ◽  
Mahmoud Mohamed Zaki ◽  
Abdelrahman I. Abushouk ◽  
Gregory Y. H. Lip ◽  
...  
Keyword(s):  
Systematic Review ◽  
Primary Prevention ◽  
Older People ◽  
Lower Risk ◽  
Observational Studies ◽  
Meta Analysis ◽  
Case Control ◽  
Current Evidence ◽  
All Cause Mortality ◽  
Statin Use

Abstract Background Current evidence from randomized controlled trials on statins for primary prevention of cardiovascular disease (CVD) in older people, especially those aged > 75 years, is still lacking. We conducted a systematic review and meta-analysis of observational studies to extend the current evidence about the association of statin use in older people primary prevention group with risk of CVD and mortality. Methods PubMed, Scopus, and Embase were searched from inception until March 18, 2021. We included observational studies (cohort or nested case-control) that compared statin use vs non-use for primary prevention of CVD in older people aged ≥ 65 years; provided that each of them reported the risk estimate on at least one of the following primary outcomes: all cause-mortality, CVD death, myocardial infarction (MI), and stroke. Risk estimates of each relevant outcome were pooled as a hazard ratio (HR) with a 95% confidence interval (CI) using the random-effects meta-analysis model. The quality of the evidence was rated using the GRADE approach. Results Ten observational studies (9 cohorts and one case-control study; n = 815,667) fulfilled our criteria. The overall combined estimate suggested that statin therapy was associated with a significantly lower risk of all-cause mortality (HR: 0.86 [95% CI 0.79 to 0.93]), CVD death (HR: 0.80 [95% CI 0.78 to 0.81]), and stroke (HR: 0.85 [95% CI 0.76 to 0.94]) and a non-significant association with risk of MI (HR 0.74 [95% CI 0.53 to 1.02]). The beneficial association of statins with the risk of all-cause mortality remained significant even at higher ages (> 75 years old; HR 0.88 [95% CI 0.81 to 0.96]) and in both men (HR: 0.75 [95% CI: 0.74 to 0.76]) and women (HR 0.85 [95% CI 0.72 to 0.99]). However, this association with the risk of all-cause mortality remained significant only in those with diabetes mellitus (DM) (HR 0.82 [95% CI 0.68 to 0.98]) but not in those without DM. The level of evidence of all the primary outcomes was rated as “very low.” Conclusions Statin therapy in older people (aged ≥ 65 years) without CVD was associated with a 14%, 20%, and 15% lower risk of all-cause mortality, CVD death, and stroke, respectively. The beneficial association with the risk of all-cause mortality remained significant even at higher ages (> 75 years old), in both men and women, and in individuals with DM, but not in those without DM. These observational findings support the need for trials to test the benefits of statins in those above 75 years of age.

Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies

2015 ◽  
Vol 41 (6) ◽  
pp. 554-567 ◽  
Author(s):  
Shanliang Zhong ◽  
Xiaohui Zhang ◽  
Lin Chen ◽  
Tengfei Ma ◽  
Jinhai Tang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Patients ◽  
Observational Studies ◽  
Meta Analysis ◽  
Statin Use
Sign in / Sign up

Export Citation Format

Share Document